The company developed the new version with input from veterinary surgeons, nurses and APPCC (Association of Private Pet Cemeteries and Crematoria) members.
Their recommendations, which have now been incorporated into the new design, include:
The new Pet Porters will be available from leading veterinary wholesalers from May.
However, MDC says that if you want to pre-order before the end of April, an introductory 10% discount is available on its website www.mdcexports.co.uk
The book is described as giving comprehensive information to support the diagnosis and treatment of commonly seen pathologies of dogs and cats, such as haematology, immunology, diagnostic imaging, respiratory diseases, cardiovascular medicine, reproductive system disorders, gastrointestinal disorders, as well as hepatobiliary and exocrine pancreas disorders.
Each chapter has been authored by an internationally recognised expert in their field.
Improve says its books support delegates studying for its Postgraduate Certificate, but are also a useful reference source for other veterinary surgeons.
John Douglass, General Manager of Improve International, said: "Following the positive response to our first textbook, the Improve International Manual of Small Animal Surgery, we felt it was important to follow up with a small animal medicine equivalent. We’re therefore very happy to unveil volume one of the Improve International Manual of Clinical Small Animal Internal Medicine and look forward to the launch of the second volume later this year."
He added: "Our textbooks focus on the practical application of current veterinary knowledge, offering top tips and key advice throughout expressed in an engaging and highly visual format to ensure that they are perfect for those in need of a quick ‘look up’ in practice.”
The new books can be bought from www.improveinternational.com/uk/books, www.5mbooks.com or from booksellers worldwide. They are also available in Spanish with translations into additional languages planned.
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
A Lincolnshire couple desperate to find an alternative to Elizabethan veterinary collars, after their dog Tess suffered a traumatic experience, have invented a new range of wound coverings called Cozi-fit.
According to Terri and Dave Ward from Skellingthorpe near Lincoln, who designed the new product, Cozi-fit is the clear alternative to Elizabethan or Buster collars. It comes in five different sizes, and the couple say that Cozi-fit is already going down well with vets and pet owners alike.
The idea for the Cozi-fit came about after the Ward's dog Tess had a hysterectomy. Dave said: "The hysterectomy was stressful enough, but Tess then had to wear a collar to stop her licking the wound. We also had to isolate her from our other dogs and she quickly became depressed and stopped eating.
"We were so worried about her that I decided to try and make a replacement using a pillowcase which we attached to her collar and fastened round her torso and hindquarters. As the wound was covered she could be around our other dogs and her movement wasn't restricted in any way.
"I was so delighted with the result that I decided to refine my design and took it to our local vet to get his opinion and it kind of grew from there. The wound coverings now come in five different sizes to suit all dogs and cats and are made from durable cotton fabric.
"We now supply over 30 veterinary surgeries including a number of Companion Care vet surgeries as well as the RSPCA and are currently in negotiation with retailers up and down the country."
Peter Munro from Whitegates Veterinary Practice said he was impressed when Terri first came to him with her initial idea: "Cozi-fit wound covers have proved to be a great benefit in protecting abdominal and castration wounds from self-trauma, especially where collars are not well tolerated and we've had some really positive feedback from our clients."
Although the product has been well received since coming on the market Dave says there are still thousands of vets, breeders and pet owners who are unaware of Cozi-fit.
"Vets perform over three million operations every year in the UK, many of which will be neuters, caesarean sections or other types of abdominal surgery, and Cozi-fit is ideal for these types of procedures.
"It is easy to fit, allows free and natural movement at all times and is a more pleasant experience for both the animal and their owner."
For more information about Cozi-fit please visit http://www.cozi-fit.com/.
Bayer Animal Health has obtained two new licensed indications for its antiparasiticide, Advocate.
The first is that the product is now licensed for the treatment of Crenosoma vulpis using a single dose. The second is that in addition to the existing treatment of Angiostrongylus vasorum claim, Advocate is now indicated for its prevention, using monthly spot-on applications.
This comes at a time when, according to Bayer, independent market research shows that vets are diagnosing Angiostrongylus vasorum at an increasing rate. Figures for 2010 place the incidence of vets who have confirmed cases at 37%, more than double the 16% confirmed in 2008, with a further 19% of vets reporting suspected cases.
Bayer is also stepping up its 'Be Lungworm Aware' consumer campaign, with the addition of a local and national radio campaign throughout October. The public information style advert will warn owners of the dangers associated with the parasite A.vasorum, and urging them to stay vigilant for signs their dog may be infected.
Veterinary staff can also direct clients who wish to learn more about lungworm to http://www.lungworm.co.uk/.
For more information on Advocate, please contact your sales representative or telephone Bayer on 01635 563000.
Their study, which was published in the research journal PeerJ at the end of last year1, investigated the effects of insulin on equine hoof lamellar cells in the laboratory.
The researchers say that high levels of insulin have been known for some time to cause acute endocrine laminitis, seen when ponies and certain types of horses graze lush pasture or consume a starch- or sugar-rich diet, or when they develop Cushing’s syndrome.
Many ponies and horses at risk of the condition produce large spikes of insulin in their blood stream after consuming meals high in non-structural carbohydrates (in particular starch and simple sugars) which indicates that this could be the way in which they succumb to acute endocrine laminitis.
The mechanism by which insulin can cause effects in the foot leading to laminitis has been the subject of much debate in recent years.
Hormones like insulin must interact with a specific receptor on the surface of cells in order to produce their effects. What has confused researchers in the past is that there appear to be no insulin receptors on the hoof lamellar cells (these cells give the lamellar tissues their strength and changes to their growth or structure weaken the bonds and cause laminitis).
The researchers considered the close similarities between insulin and a growth factor hormone called insulin-like growth factor -1 (IGF-1). There are receptors for IGF-1 on the lamellar cells, and the researchers speculated that high concentrations of insulin might be able to cross-stimulate these cells by activating the IGF-1 receptors. To investigate this possibility PhD student Courtnay Baskerville, together with her supervisor Professor Simon Bailey, developed a method for culturing lamellar epithelial cells in the laboratory, and incubated them with increasing concentrations of insulin.
They found that high concentrations of insulin stimulated the cells to proliferate. Furthermore, this effect could be prevented using an antibody that specifically blocks only the IGF-1 receptor. Further downstream effects within the cells were also shown. The changes seemed to occur mainly at very high concentrations of insulin. Similar concentration levels can be seen in ponies and horses with insulin dysregulation linked to Equine Metabolic Syndrome, but are not commonly seen in normal horses that are considered to be at lower risk of laminitis.
Further work is now ongoing to determine exactly how these cellular changes induced by sustained high insulin concentrations might cause laminitis. However, it seems that targeting the IGF-1 receptor may be an option for developing new drugs to prevent and treat laminitis.
Professor Simon Bailey said: "The information gathered in this study provides the equine industry worldwide with valuable insights into the causes of the common and serious condition of laminitis. The research group would like to acknowledge the support of the Waltham Centre for Pet Nutrition, in particular the involvement of Professor Pat Harris.”
Reference
The module, which was produced with Ian Wright, head of the specialist parasitology organisation, ESCCAP, aims to help veterinary professionals with their discussions with pet owners about parasite management.
Andrea Tarr, Veterinary Prescriber’s founder and director said: "Surveys across Europe have shown that the public have poor understanding about the need for endoparasite control in their pets, including the risks endoparasites pose, such as zoonosis, and about routine preventative treatment."
The Veterinary Benevolent Fund has launched a short film about a veterinary surgeon's experience of severe depression and her inspiring recovery.
The charity says it hopes the film, published on the Vetlife website today, will encourage the veterinary profession to talk more openly about stress and depression in the workplace and will motivate veterinary employers to adopt best practice in supporting their staff's mental health.
Nick Short, the VBF Director responsible for the development of the Vetlife website, said: "We are so grateful to the veterinary surgeon concerned for having the courage to share her story and for her insights into what could be done to make recovery easier for other vets. We were delighted to hear that she felt she was treated well and got the help she needed from the Veterinary Benevolent Fund and the Veterinary Surgeons' Health Support Programme.
"Recent press reports have estimated that the cost to the UK economy of stress, depression and suicide is £26 billion per year. We know that the profession has a high incidence of these problems, so it follows that depressive illness must have an alarming economic effect on it. This means it is essential to invest in improving awareness and support.
"The VBF wants to produce more web videos on issues that veterinary surgeons, students or nurses commonly encounter such as debt, addiction, professional conduct or employment problems. However, we need to secure additional sponsorship in order to fund this work - each 5 minute video will cost about £2,500 to produce. If you or your organization would be interested in supporting this work, please contact the VBF office at 7 Mansfield Street, London W1G 9NQ, telephone 020 7908 6385 or email info@vetlife.org.uk. Donations can also be made online at www.justgiving.com/VBF"
Rory O'Connor, National Co-ordinator at the Veterinary Surgeons' Health Support Programme said: "Many of us will have mental health problems at some point in our lives but most can make a full return to work with the right support. As highlighted in the film, it is really helpful if employers are willing to explore adjustments to working conditions or to the working environment such as flexible working hours or changes to working responsibilities. I am always available to help both employers and employees with these kinds of discussions and we are currently developing content on mental health support in the workplace for the Vetlife website. All advice is completely confidential."
The film was made by John Somers and Ben Sheriff at the University of Exeter using an actress to speak the words of the veterinary surgeon.
Boehringer Ingelheim Vetmedica has launched Benefortin (benazepril hydrochloride), an ACE inhibitor licensed for the treatment of congestive heart failure (CHF) in dogs. It is also licensed for the treatment of chronic renal insufficiency (CRI) in cats.
Benefortin uses novel micro-cap technology to mask the taste of the bitter molecule. According to Boehringer, this ensures that Benefortin tastes good1, even if it is bitten, crunched or chewed. The company says taste tests demonstrated 100% palatability in dogs and 92% palatability in cats in home settings1.
Benefortin is available in 5mg and 20mg tablets for dogs and 2.5mg tablets for cats and dogs.
Jemima Scott, Boehringer Ingelheim brand manager said: "The addition of Benefortin to our cardiology portfolio now enables us to provide veterinary practices with two of the cornerstones of canine CHF treatment, and the palatability of Benefortin makes it an excellent choice for vets needing to prescribe an ACE inhibitor."
To support the launch of Benefortin, Boehringer is offering veterinary practices the opportunity to win one of three Bosch microwave ovens in a prize draw by answering three multiple choice questions on the ACE inhibitor.
For further information on Benefortin, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.
The new distribution service uses Invatech's Patient Medication Record (PMR) system, called Titan, which was accredited by the NHS a little over a year ago. Titan has now been developed further to support the company's Home Pharmacy service, and integrate with MWI.
The company says the new system offers practices a seamless workflow between prescribing, dispensing and logistics systems.
Tariq Muhammad, CEO of Invatech Health, said: "“The use of PMR systems for the veterinary market has been very light touch until now. Knowing that that we can bring the same level of efficiency and workflow to a new market presents an opportunity to support animal health in the same way that we do for human health."
Alan White, Commercial Director at MWI Animal Health, said: “The Covid pandemic has presented many challenges to veterinary professionals in the UK. Travel restrictions and social distancing measures make it difficult for animal owners to collect the medications and treatments they need from veterinary practices.”
“We are excited to be able to work with Invatech to provide an innovative solution to this problem, where vets can send the medications needed directly to their client. Working in partnership with veterinary practices and Invatech means we can move animal health forward together.”
For more information, visit: https://www.invatechhealth.com/
The service is being led by Isuru Gajanayake, a board-certified specialist in veterinary nutrition. He said: “Since launching our clinical nutrition service last year, we have seen a number of cases in which patients have been either dehydrated or malnourished, sometimes both.
“Working alongside our other services in a truly multidisciplinary approach, we have been able to offer suitable treatment to support a significant number of dogs and cats.
“With the launch of the parenteral nutrition service, we can now expand this offering and, in doing so, become one of only a very few referral centres across the UK to provide this as a specialist service.
“Patients who are given parenteral nutrition will be hospitalised in our advanced intensive care unit to ensure they can be monitored closely by our specialist emergency and critical care (ECC) team, who provide exceptional expertise in critical care and treatment for every patient when they need it most.
Isuru added that the addition of the clinical nutrition and parenteral nutrition services at Willows ensures that there is a much greater emphasis on nutrition and hydration for all patients at the centre, whatever their underlying illness.
For more information, visit www.willows.uk.net or search for Willows Veterinary Centre and Referral Service on Facebook.
Trilotab is licensed for the treatment of pituitary-dependent hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma, which accounts for 85% of spontaneous cases of Cushing’s, and for the treatment of adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT), which accounts for the remaining 15% of spontaneous cases1.
The new tablet is divisible into halves and quarters to facilitate dose adjustment and make administration easier.
Divided tablets remain stable outside of the blister packaging until the next dose is due, thereby avoiding wastage.
Trilotab tablets are chewable and chicken-flavoured to help improve treatment compliance.
They contain hydrolysed chicken flavouring so they can be prescribed for pets allergic to chicken.
Trilotab is administered once daily with food with a starting dose of 2mg trilostane/kg bodyweight.
The new tabs are available in three presentations: 10mg, 30mg, and 60mg presentations, which Virbac says should help practices reduce their dispensary stockholding.
Andrew Connolly, Marketing Director – UK & Ireland at Virbac, said: ‘The complex nature of Cushing’s syndrome in dogs can make it a challenging condition to manage for both the clinician and the pet owner.
"With the requirement for lifelong treatment, it is our hope that Trilotab’s easy administration and simplified dosing protocols will genuinely help to improve the lives of dogs affected by the disease, whilst making the clinician and pet owner’s lives just a little bit easier too!"
Intervet /Schering-Plough Animal Health has announced plans for a third National Vaccination Month Campaign to take place in May.
The campaign, which is aimed at owners of unvaccinated animals, is being fronted by TV presenter and wildlife expert Chris Packham. Intervet / Schering-Plough says it hopes the initiative will counter falling rates of pet vaccination that have been seen since the credit crunch.
In the lead up to National Vaccination Month, the company will be running a pet health awareness national and regional PR campaign backed up by print and TV advertising.
Pet owners will be able to download a voucher for a discounted vaccination in May from http://www.nvmonline.co.uk/. As well as dogs, cats and rabbits, horses will be included in the scheme for the second time.
During the last National Vaccination Month in June 2009, 1022 surgeries participated nationwide and an additional 40,000 animals were vaccinated as a result - 8,000 up on the first campaign run in 2008. According to Intervet / Schering-Plough, many practices saw more than 100 vouchers being redeemed.
The 2009 campaign came after more than a quarter of vets surveyed by Intervet reported concerns about falling levels of vaccination because of the credit crunch. Following the recession and public fears over the deficit, there are concerns that pet owners will cut back even further.
Angus Robinson from Intervet / Schering-Plough Animal Health said: "Research shows that the main reason why people don't vaccinate their pets is a lack of awareness of disease risk. We are also concerned that given the current pressures on household budgets, more people are deciding to cut back on vaccinating their animals with the real risk that this may have a potential effect on levels of herd immunity in the longer term."
He added: "We listened to practices which took part in NVM 2009 and have invested in improving the website to offer a simpler system for surgeries to download and log vouchers for their clients. The site will also drive pet owners to participating vets more quickly. Social media has taken off in a big way since our first campaign in 2008 and we will also be using Facebook and Twitter this time to reflect that. We are hoping that this will reach younger pet owners as data from our last campaign showed that pet owners in their 20s and early 30s were the age group least likely to vaccinate their animals."
Jane Carter of the Drove Veterinary Hospital in Swindon said: "National Vaccination Month is a golden opportunity to communicate the key preventative healthcare messages to new and existing clients. There was a significant outbreak of parvovirus in our area last summer which got a lot of publicity so we are expecting people will really catch onto the campaign this time."
Intervet / Schering-Plough Animal Health veterinary customers planning to take part in National Vaccination Month 2011 can log onto www.nvmonline.co.uk to complete the registration process.
This third biennial offering from GB’s Cattle Health and Welfare Group also contains a summary of progress on endemic disease control with advances in eradicating Bovine Viral Diarrhoea (BVD) in each country highlighted.
The Chief Veterinary Officers of UK, Scotland and Wales have welcomed the publication of the report saying that as the possible impacts of the referendum on leaving the EU are considered, the importance of a GB focus on disease control is as important as ever.
In their joint forward, Nigel Gibbens, Sheila Voas and Christianne Glossop said: "The healthier our animals, the more attractive our products. The better our animal welfare, the greater the confidence of consumers in our production systems.
"With the UK Government placing AMR at the top of its risk register alongside terrorism and pandemic ’flu, it is heartening to see that CHAWG, in common with other livestock sectors, has grasped the nettle in looking first at how the cattle sector can better capture data on use of antimicrobials."
They go on to say that addressing AMR helps address other imperatives as an emphasis on sound animal husbandry and healthy animals kept to high welfare standards will help minimise routine reliance on antimicrobials: "Success in controlling endemic disease is one area of considerable importance, and here we can highlight CHAWG’s pivotal role in the development and promotion of national disease control programmes. These include the launch of the BVDFree scheme in England earlier this year, ongoing progress with BVD eradication in Scotland, the development of a Wales BVD scheme, and the Action Johne’s initiative."
In the report’s conclusion, RSPCA’s head of farm animals Marc Cooper points out that it is clear many positive initiatives are being pursued within the industry. He said: "Notable amongst these are those associated with dairy cow genetics, eliminating BVD, the national dairy cow welfare strategy and the development of a data hub for the collation of information relating to antimicrobial use.
"Indeed, some of these are starting to realise improvements in key areas, for example, dairy cow longevity is beginning to increase, and cow fertility figures and somatic cell counts appear to be moving in the right direction.
"However, there are still ongoing concerns relating to some important health and welfare issues. For example, despite the evidence suggesting the annual prevalence levels of cattle lameness are beginning to fall, there still appears to be no centralised database for recording it."
Chairman of CHAWG Tim Brigstocke says the contributed comments are encouraging and provide positive direction for future CHAWG activities. He also reassures that while this report sees a number of advances in highly topical areas, ‘core’ activities are not being ignored. He said: "Effective farm health planning remains the bedrock of good practice. And while we tend to focus on areas which need improvement, it’s worth mentioning that a delegation from the Food & Veterinary Office (FVO) of the European Commission recently visited and were impressed by the coordinated approach taken in this country."
The report can be downloaded from www.chawg.org.uk.
Francisco says he decided to launch the podcast after watching how the bond between society and veterinary professionals has been eroded in recent years, with vets increasingly being portrayed as money-grabbers and uncaring in the press.
The aim of the podcast is to show the human behind the surgical mask; that veterinary professionals have the same feelings, motivations, worries and passions as anyone else.
Francisco said: "For those who aren’t part of the veterinary community, I hope to open a window into who we are, so they can better understand what drives our behaviours, decisions and compassion. And for those who are, I hope to make them feel that they’re not alone."
More Than Just a Vet is open for everyone to listen to directly from the website morethanjustavet.net, where you can subscribe to be alerted when there's a new release. The podcast is also available on all major podcast providers.
The Boehringer Academy (www.boehringer-academy.co.uk) contains hundreds of hours of CPD material on equine, companion and production animals. It comprises a mixture of webinars, podcasts, short videos and downloadable documents, which can be viewed at any time. The site keeps a CPD log for each user and provides downloadable certificates.
Boehringer’s Small Animal Marketing Team Leader, Jemima Mead said: "We already have just over 15,000 vets and nurses in the UK and Ireland currently registered with the Academy.
"New and existing members are eligible to receive the Boehringer Academy colouring book. They simply have to visit www.boehringer-academy.co.uk and complete their profile. In addition, everyone completing their profile will be entered into a draw to win an iPad Pro and Apple Pencil."
Vet Direct says the unit, which is used for the diagnosis and monitoring of anaemia in dogs, cats and horses, requires only a simple ear-prick test to deliver a result.
Leon Wright, managing director at Vet Direct, said: "The AniPoc device eliminates the need to draw blood with a syringe, a simple pin prick is enough, and is perfect for both veterinary practices and home visits.
"The speed and accuracy of the product means that it is better equipped to monitor animals undergoing anaesthesia or transfusions, and can be used to effectively screen animals taking part in Pet Blood Banks and mobile clinics."
Vet Direct says the AniPoc also delivers results much faster than a centrifuge and doesn’t require any time to be spent in the lab; a process which can take 10-20 minutes to get a result - by which time they are often out-of-date in critical cases.
The AniPoc Handheld Monitor and Starter Kit is available from Vet Direct for £250.
For more information, visit www.vet-direct.com or call 0800 068 3300.
Presented by Sam Taylor BVetMed(Hons) CertSAM DipECVIM-CA MANZCVS FRCVS, the webinar will also be available to watch on demand later, for those who miss it.
Sam is an Internal Medicine and Feline Specialist and current ISFM Academy lead.
She recently chaired and co-authored the ISFM guidelines on the management of the inappetent hospitalised cat.
The webinar, which counts for one hour’s CPD, will cover:
Sarah Musgrave, Brand Manager at Dechra, said: “Inappetence is a common reason cats present to veterinary practices and it can be caused by multiple conditions.
"Management needs to look beyond just treating the underlying disease as factors such as stress, nausea and pain can play a significant role.
"Untreated inappetence has a substantial negative effect on recovery from illness and surgery, makes medicating cats difficult and may even hasten euthanasia decisions.
"The ‘Feline pawsative about feline inappetence?’ webinar will help educate on feline weight loss, why intervention to improve nutrition is important and the practical steps to treating inappetence.”
https://thewebinarvet.com/webinars/feline-pawsative-about-feline-inappetence.
Agrimin has announced the launch of a new range of boluses for sheep and cattle that use 'eroding technology' to deliver a sustained supply of three trace elements for up to 180 days:
According to Agrimin, each bolus is designed to provide the full daily requirement of cobalt and selenium and the largest available daily supply of iodine to both cattle and sheep. The boluses do not contain any copper, an element known to cause issues in certain parts of the country, in closely managed dairy cows or in continental sheep breeds.
Each bolus is made up of two parts, held together by a soluble wrapper. After administration, the wrapper dissolves and the two halves remain in the reticulum where they erode and dissolve. This process delivers a continuous and regular supply of nutrients to the animal.
Agrimin's Dr Jamie Bennison said that the new range has been extensively trialled in New Zealand and at Glasgow Veterinary School: "Trials have confirmed a sustained release profile which ensures that iodine, selenium and cobalt levels are maintained throughout the active life of the bolus. In farm trials this has translated into higher levels of the elements in blood samples and improved animal productivity."
Treatment is one bolus per animal (48g for sheep; 160g for cattle) administered with an Agrimin bolus gun. One bolus is sufficient to meet the animal's full daily requirement for 180 days.
For more information about the 24•7 Iodine•Selenium•Cobalt range of cattle and sheep boluses, please visit http://www.agrimin.com/ or call 01652 688046.
Independent research carried out by CM Research amongst practising companion animal veterinary surgeons has placed VetSurgeon.org in the top 5 veterinary media publications, and the leading online destination by a considerable margin.
As part of the research, 300 vets were asked which media publications they followed. Unprompted, 24% answered VetSurgeon.org, placing the site in 5th place alongside such venerable titles as Veterinary Times, Veterinary Record and The Journal of Small Animal Practice.
Carlos Michelsen, Managing Director of CM Research said: “The answer to this question was unprompted, so the leading titles will likely have benefited from the greater brand awareness that comes from having their magazines delivered to the practice, and the fact that they’ve been in existence for so much longer than VetSurgeon.org. That makes this an even more remarkable achievement for the site."
In terms of online media used by veterinary surgeons, VetSurgeon.org was the clear winner, by a number of lengths. Where 24% of vets said they followed VetSurgeon.org, only 5% followed the second placed website published by Vet Times. Indeed the percentage of vets reported as following VetSurgeon.org was very nearly the same as the percentage that visited all the other veterinary websites combined.
Arlo Guthrie, Publishing Editor of VetSurgeon.org said: “I’m over the moon. When I set up VetSurgeon.org 8 years ago, people said ‘it’ll never work’. So to be sitting here talked about in the same breath as a title like the Veterinary Record, which has been around for 125 years, fills me with a huge sense of pride.
“If I’m allowed my little ‘Oscar’ moment, I would like to thank the members of VetSurgeon.org, without whom none of this would have been possible. I know, it’s a dreadful cliché, but the success of VetSurgeon.org is entirely down to its members, both those who actively participate in the forums and those who just come to read content. I am enormously grateful to you all.
“I’m also hugely excited about the future. We’ve got so much in the pipeline - all designed to further help the sharing of knowledge and experience within the profession. Stay tuned!"
During the 60 days before to 30 days after calving, dairy cows experience a dip in their natural immunity, leaving them especially vulnerable to important diseases such as mastitis2, metritis3 and retained placenta.4 With serious cost consequences and implications for cow welfare and productivity, this makes the transition period one of the most challenging yet vital periods for vets to manage with dairy clients.
Imrestor (pegbovigrastim injection) is a pegylated form of the naturally occurring protein cytokine, bovine Granulocyte Colony Stimulating Factor (bG-CSF). Elanco says it helps restore the cow’s natural defences by increasing the number and restoring the function of neutrophils, the primary type of white blood cell that recognizes and kills harmful bacteria.
Fiona Anderson, Technical Vet at Elanco, said: "It’s no secret that a successful transition period is vital for maximising productivity in the next lactation, yet we are still ‘firefighting’ common transition diseases like mastitis rather than focusing on their true cause."
"Vets are under increasing pressure to adopt a more proactive approach, not least to reduce the use of antibiotics in livestock but with few credible alternatives. This can be challenging in dairy herds, particularly around calving when cows are susceptible to multiple disease challenges while their defences are low. Imrestor helps to restore a cow’s own natural immunity and strengthen her ability to defend against infection by a range of mastitis pathogens – thus helping to protect the cow against mastitis when she needs it most."
Available in pre-filled, single-dose syringes, Imrestor is administered with two injections – one seven days prior to the anticipated date of calving and the other within 24 hours after calving – with neither injection requiring a withdrawal period.
Kingsley Baxendale, Ruminant Marketing Manager at Elanco Animal Health said: "It can be extremely frustrating for vets to see their dairy farmers struggling with the stress and hassle of dealing with increased numbers of sick cows during calving; they have enough to deal with at the moment. We’re delighted that Imrestor can provide vets with a tool to help decrease the negative consequences associated with immune-related diseases like mastitis and maximise their herds’ lactation potential."
As part of the launch of Imrestor, Elanco also announced its new 'Pledge To Protect' initiative to encourage vets and farmers to make a pledge symbolising their commitment to address immune suppression in their dairy cows.
The number of pledges will be tracked using a life-sized 2D cow model, pictured above. For each pledge, which can be made online or at events, Elanco will make a £5 donation to The Royal Agricultural Benevolent Institution (R.A.B.I), which supports farmers in difficulty. As a thank you for showing support, all pledgers will automatically be entered into a weekly prize draw.
To find out more about using Imrestor and how you can make your pledge, visit www.vital90days.co.uk.
References
Ceva says CLAS vials are proven to be easy to use, practical and eco-friendly and are preferred by 99% of farmers on farm1. They have 33% less impact on the environment from cradle to grave than glass2 and are robust and shock resistant3 for fewer breakages and losses. They are made from a lightweight material to make the vials easier to be transported and handled4 and have an ergonomic ‘grip groove’ for easier handing5.
Peter Keyte, ruminant business unit manager at Ceva Animal Health said: "Ceva’s CLAS vials are hugely popular with both vets and farmers due to their practicality, ease of use and environmental credentials.
“We are therefore delighted that Ketofen has joined the extensive range of livestock injectables available in CLAS.”
For further information contact your local Ceva territory manager, call Ceva on 01494 781510 or email cevauk@ceva.com.
The RCVS Disciplinary Committee has reprimanded and warned as to his future conduct a Hampshire veterinary surgeon found guilty of serious professional misconduct for cumulative failures to provide adequate professional care, and insufficient regard for animal welfare whilst treating a dog that had ingested broken glass.
The sanction was decided following a 12-month postponement of a decision ordered at a hearing on 19 November 2010.
At last week's hearing, the Committee was asked to decide what sanction would be appropriate in the case of Peter Ardle MacMahon for his treatment of a Cocker Spaniel called Wilfred, while working as a locum in Portsmouth. In 2010, the Committee found that Mr MacMahon had not removed the ingested glass from Wilfred's stomach or adequately checked that he had done so; had inadequately prevented abdominal contamination; and, had failed to communicate this contamination problem to Wilfred's usual veterinary surgeon. Considering these charges cumulatively, the Committee found that the treatment Mr MacMahon provided to Wilfred had fallen far short of the standard to be expected in the profession and amounted to serious professional misconduct.
Shortly prior to treating Wilfred, Mr MacMahon had returned to practice after a ten-year absence and, at last year's hearing, agreed to comply with undertakings regarding his professional development. These included performing at least 70 hours of medical and surgical continuing professional development (CPD); providing the Disciplinary Committee Chairman with quarterly CPD reports and two employer reports regarding his competence; observing 24 days of current practice by shadowing another veterinary surgeon; and, providing reports from this veterinary surgeon as to his competence and a case diary.
The Committee considered the factual findings from the November 2010 hearing and the concerns then expressed about Mr MacMahon's conduct and capabilities as a veterinary surgeon, as well as his compliance with the agreed undertakings. As advised by the Legal Assessor, the Committee's considerations of sanction began at the lowest level that would ensure that the welfare of animals was properly protected; that proper standards would be maintained among practitioners in the profession; and, that would be in the interests of the public.
Speaking on behalf of the Disciplinary Committee, Chairman Professor Peter Lees said: "The Committee is satisfied that the respondent had complied fully with the spirit of the requirements of the undertakings he had entered into on 18 November 2010. Indeed, the view is that the respondent has done well to achieve the level of compliance that he has, given that he had suffered a period of significant ill-health during the period since he entered into those undertakings.
"The ultimate decision is that the respondent's conduct [...] warrants the imposition of at least a reprimand," he continued. "However, it is also the Committee's firm view that the respondent must be warned about his future conduct so that he will know the Committee considers he needs to maintain the level of continuous professional development that he has achieved [over the last] 12 months, and to have constantly in mind the paramount obligation of all veterinary surgeons to ensure the welfare of animals under their care.
"Such a warning as to future conduct should, and the Committee believes that it will, serve as a constant reminder to the respondent that he must undertake only those procedures, and only proffer professional advice, in the areas where he has the requisite up-to-date skills, knowledge and experience."
The Committee reprimanded Mr MacMahon and warned him as to his future conduct.
Fort Dodge Animal Health has announced that its Zulvac 8 Ovis® Bluetongue sheep vaccine is now licensed and available in the UK. The company believes that the product will provide significant benefits to sheep farmers.
Zulvac 8 Ovis® is an inactivated adjuvanted vaccine for the active immunisation of sheep by subcutaneous injection against Bluetongue Serotype 8. It also provides a reduction in viraemia. Administration is a two x 2 ml dose primary course in year one but only a single shot booster in the second year.
The use of Zulvac 8 Ovis as a booster for animals previously vaccinated with a primary course from other manufacturers is in line with Defra (2009) guidance: 'No problems are anticipated with re-vaccinating animals which have already received a primary course of vaccination with a different vaccine 1'.
The first dose can be administered from one month of age and Zulvac 8 Ovis® is proven for use in pregnant sheep. The onset of immunity is provided 25 days after the second dose.
Fort Dodge says Zulvac provides cost savings to farmers through its pricing strategy. While the price for the two dose primary course is competitive with alternative vaccines, for animals which were vaccinated last year and require only a single shot booster, the cost will be half that of competitive offerings, providing a significant incentive to farmers to vaccinate.
The vaccine is supported by a specific Zulvac Ovis fixed 2ml dose applicator with Sterimatic needle protector and cleaning system which aids administration and hygiene and is sold separately.
David Bartram MRCVS, Veterinary Technical Manager at Fort Dodge, said: "Sheep farmers have been waiting for a Bluetongue vaccine which offers a cost effective solution to vaccination - particularly for animals which received their primary course last year and are simply in need of a booster. We expect the fact that it's licensed for use in pregnant sheep to also prove attractive.
"Zulvac 8 Ovis® is the latest addition to Fort Dodge's Zulvac range for both cows and sheep. It is already used in Europe and has helped protect millions of animals."
The webinar, titled: ‘When the coughing won’t stop…. what to do when standard BRD treatment protocols aren’t getting to the bottom of it’, aims help vets manage complex outbreaks that happen despite best practice management and treatment protocols.
The full programme includes:
The event is being held live so you can submit questions to the speakers, but the session will be recorded, so it can be watched again later.
Attendees will receive a certificate for one hour of CPD and the link to the recorded webinar.
To register, email the event team by 27 November 2020 at brdwebinar-group@ceva.com. In the email, please give your name and the email address to which you would like the registration link sent.